ZENBEXUS
Aug 24, 2026
BMS Claims the First CELMoD Crown as ZENBEXUS Raises the Stakes in Multiple Myeloma Treatment
Summary In August 2026, the FDA granted accelerated approval to Bristol Myers Squibb’s ZENBEXUS (iberdomide), the first-in-class CELMoD, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy. Approval rests on the Phase 3 EXCAL...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
